Literature DB >> 36252992

Cardiac care of children with dystrophinopathy and females carrying DMD-gene variations.

John Bourke1,2, Cathy Turner2, William Bradlow3, Ashish Chikermane4, Caroline Coats5, Matthew Fenton6, Maria Ilina7, Alexandra Johnson8, Stam Kapetanakis9, Lisa Kuhwald8, Adrian Morley-Davies10, Ros Quinlivan11,12, Konstantinos Savvatis12,13, Marianela Schiava2, Zaheer Yousef14, Michela Guglieri2.   

Abstract

OBJECTIVE: We provide succinct, evidence-based and/or consensus-based best practice guidance for the cardiac care of children living with Duchenne muscular dystrophy (DMD) as well as recommendations for screening and management of female carriers of mutations in the DMD-gene.
METHODS: Initiated by an expert working group of UK-based cardiologists, neuromuscular clinicians and DMD-patient representatives, draft guidelines were created based on published evidence, current practice and expert opinion. After wider consultation with UK-cardiologists, consensus was reached on these best-practice recommendations for cardiac care in DMD.
RESULTS: The resulting recommendations are presented in the form of a succinct care pathway flow chart with brief justification. The guidance signposts evidence on which they are based and acknowledges where there have been differences in opinion. Guidelines for cardiac care of patients with more advanced cardiac dystrophinopathy at any age have also been considered, based on the previous published work of Quinlivan et al and are presented here in a similar format. The recommendations have been endorsed by the British Cardiovascular Society.
CONCLUSION: These guidelines provide succinct, reasoned recommendations for all those managing paediatric patients with early or advanced stages of cardiomyopathy as well as females with cardiac dystrophinopathy. The hope is that this will result in more uniform delivery of high standards of care for children with cardiac dystrophinopathy, so improving heart health into adulthood through timely earlier interventions across the UK. © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cardiac imaging techniques; cardiomyopathy, dilated; genetics; outcome assessment, health care; pharmacology, clinical

Mesh:

Year:  2022        PMID: 36252992      PMCID: PMC9577913          DOI: 10.1136/openhrt-2022-001977

Source DB:  PubMed          Journal:  Open Heart        ISSN: 2053-3624


  70 in total

1.  107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands.

Authors:  K Bushby; F Muntoni; J P Bourke
Journal:  Neuromuscul Disord       Date:  2003-02       Impact factor: 4.296

Review 2.  Challenges in management of left ventricular thrombus.

Authors:  Fuad Habash; Srikanth Vallurupalli
Journal:  Ther Adv Cardiovasc Dis       Date:  2017-06-07

3.  Life Expectancy in Duchenne Muscular Dystrophy: Reproduced Individual Patient Data Meta-analysis.

Authors:  Jonathan Broomfield; Micki Hill; Michela Guglieri; Michael Crowther; Keith Abrams
Journal:  Neurology       Date:  2021-10-13       Impact factor: 9.910

Review 4.  Duchenne muscular dystrophy.

Authors:  Ellen J Annexstad; Inger Lund-Petersen; Magnhild Rasmussen
Journal:  Tidsskr Nor Laegeforen       Date:  2014-08-05

5.  Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study.

Authors:  Kan N Hor; Janaka Wansapura; Larry W Markham; Wojciech Mazur; Linda H Cripe; Robert Fleck; D Woodrow Benson; William M Gottliebson
Journal:  J Am Coll Cardiol       Date:  2009-04-07       Impact factor: 24.094

6.  Presence of mechanical dyssynchrony in Duchenne muscular dystrophy.

Authors:  Kan N Hor; Janaka P Wansapura; Hussein R Al-Khalidi; William M Gottliebson; Michael D Taylor; Richard J Czosek; Sherif F Nagueh; Nandakishore Akula; Eugene S Chung; Woodrow D Benson; Wojciech Mazur
Journal:  J Cardiovasc Magn Reson       Date:  2011-02-02       Impact factor: 5.364

7.  The effect of enalapril and carvedilol on left ventricular dysfunction in middle childhood and adolescent patients with muscular dystrophy.

Authors:  Hye Won Kwon; Bo Sang Kwon; Gi Beom Kim; Jong Hee Chae; June Dong Park; Eun Jung Bae; Chung Il Noh
Journal:  Korean Circ J       Date:  2012-03-26       Impact factor: 3.243

8.  A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy.

Authors:  Hugh D Allen; Kevin M Flanigan; Philip T Thrush; Igor Dvorchik; Han Yin; Charles Canter; Anne M Connolly; Mark Parrish; Craig M McDonald; Elizabeth Braunlin; Steven D Colan; John Day; Basil Darras; Jerry R Mendell
Journal:  PLoS Curr       Date:  2013-12-12

9.  Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.

Authors:  Nadia Bouabdallaoui; Eileen O'Meara; Virginie Bernier; Michel Komajda; Karl Swedberg; Luigi Tavazzi; Jeffrey S Borer; Michael Bohm; Ian Ford; Jean-Claude Tardif
Journal:  ESC Heart Fail       Date:  2019-10-08

10.  Adult North Star Network (ANSN): Consensus Guideline For The Standard Of Care Of Adults With Duchenne Muscular Dystrophy.

Authors:  R Quinlivan; B Messer; P Murphy; R Astin; R Mukherjee; J Khan; A Emmanuel; S C Wong; R Kulshresha; T Willis; J Pattni; D Willis; A Morgan; K Savvatis; R Keen; J Bourke; C Marini Bettolo; C Hewamadduma
Journal:  J Neuromuscul Dis       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.